2m 2m 2m 2m 2m 2m 2m
ADVANCED BIOMED (ADVB)
NASDAQ
$3.55+$0.09 (+2.60%)
Price as of Oct 22, 2026 7:30 PM EDT- $6.2MMarket Cap
- -60.68%1-Year Change
- Diagnostics & ResearchIndustry
ADVANCED BIOMED (ADVB)
$3.55+$0.09 (+2.60%)
Annual
Quarterly
06/30/2026 | 06/30/2025 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 127,637 N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 127,637 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | N/A N/A | -909,771 N/A | |
Depreciation and Amortization Expense | N/A N/A | 343,830 N/A | |
Total Operating Expenses | 6.4M +110.56% | 3.0M N/A | |
Operating Profit | -6.2M +91.27% | -3.3M N/A | |
Interest Income | N/A N/A | 24,915 N/A | |
Interest Expense | -7,014 N/A | N/A N/A | |
Interest Income and Expense and Net | -7,014 -128.15% | 24,915 N/A | |
Total Nonoperating Income and Expense | -28,939 -87.84% | -237,933 N/A | |
Income before Taxes | -6.3M +92.16% | -3.3M N/A | |
Income Taxes | -1,205 -100.06% | 2.0M N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -6.3M +92.12% | -3.3M N/A | |
Net Income from Continuing Operations Applicable to Common | -6.3M +92.12% | -3.3M N/A | |
Basic EPS and Net Income | 5.33 +3,431.25% | -0.16 N/A | |
Diluted EPS and Net Income | 5.33 +3,431.25% | -0.16 N/A | |
Basic Weighted Average Shares | 1.3M -93.90% | 20.5M N/A | |
Diluted Weighted Average Shares | 1.3M -93.90% | 20.5M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 385,535 -86.72% | 2.9M N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 385,535 -86.72% | 2.9M N/A | |
Total Current Assets | 13.7M +127.92% | 6.0M N/A | |
Accumulated Depreciation | N/A N/A | 1.6M N/A | |
Property and Plant and Equipment and Net | N/A N/A | 331,346 N/A | |
Total Long-Term Assets | 1,204 -99.75% | 479,772 N/A | |
Total Assets | 13.8M +111.15% | 6.5M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | |
Total Current Liabilities | 1.5M -48.98% | 2.9M N/A | |
Total Long-Term Debt | N/A N/A | 455,992 N/A | |
Total Long-Term Liabilities | N/A N/A | 145,651 N/A | |
Total Liabilities | 1.5M -51.43% | 3.0M N/A | |
Retained Earnings | -12.6M -34.72% | -19.2M N/A | |
Total Stockholders Equity | 12.3M +253.03% | 3.5M N/A | |
Total Shares Outstanding | 1.7M -92.37% | 21.6M N/A | |
Cash Flow | |||
Cash from Operating Activities | -1.9M -66.58% | -5.8M N/A | |
Capital Expenditures | N/A N/A | 31,650 N/A | |
Cash from Investing Activities | -2.5M +7,818.13% | -31,650 N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 2.0M -66.84% | 5.9M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | -4,883.80% N/A | N/A N/A | |
Return on Assets | -61.80% N/A | N/A N/A | |
Return on Equity | -79.49% N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 9.33 N/A | N/A N/A | |
Cash Ratio | 0.26 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow